Ascentage Pharma presented initial clinical data for alrizomadlin (APG-115), an MDM2-p53 inhibitor, in pediatric patients with relapsed or metastatic solid tumors at ASCO 2026. The drug, tested alone or with lisaftoclax, showed preliminary anti-tumor activity, including complete responses in some patients, and a manageable safety profile. This marks a significant step in developing new treatments for hard-to-treat pediatric cancers, with further studies planned to confirm these findings and advance clinical development under China's SPARK Plan.
The US Department of Commerce has closed a loophole that allowed advanced AI chips from Nvidia and AMD to be exported to Chinese companies operating outside China, such as in Malaysia. This move strengthens US efforts to restrict China's access to cr...
KITE token surged 10% in the last day, reclaiming key exponential moving average (EMA) levels and improving its short-term market structure. This price rally was supported by a 53% increase in trading volume to $63 million and a 10% rise in open inte...
Ascentage Pharma presented updated clinical data at ASCO 2026 showing olverembatinib’s effectiveness as a second-line treatment for chronic-phase chronic myeloid leukemia (CML-CP). Patients achieved a 91.3% complete cytogenetic response and 60.9% maj...
Ascentage Pharma presented positive Phase Ib trial results at ASCO 2026 for olverembatinib combined with blinatumomab in patients with relapsed or refractory Philadelphia chromosome-positive leukemias, showing high response rates and manageable safet...
Atlas Salt Inc. announced a $10 million bought deal private placement, selling 8.33 million common shares at $1.20 each, with an option for underwriters to buy an additional 15%. The funds will support early works, engineering, permitting, and financ...
